Cerebral palsy (CP) remains the most significant neurological disorder associated with preterm birth. It disrupts quality of life and places huge cost burdens on society. Antenatal magnesium sulphate administration to females before 32 weeks' gestation has proven to be an effective intervention to reduce the rate of CP. In models of hypoxia, hypoxia-ischemia, inflammation, and excitotoxicity in various animal species, magnesium sulphate preconditioning decreased the resulting lesion sizes and inflammatory cytokine levels, prevented cell death, and improved long-term cognitive and motor behaviours. In humans, meta-analyses of five randomized controlled trials using magnesium sulphate as a neuroprotectant showed prevention of CP at 2 years. The benefit remained consistent regardless of gestational age, cause of preterm birth, and total dose received. Antenatal magnesium sulphate treatment is now recommended by the World Health Organization and by many obstetric societies. Its cost-effectiveness further justifies its widespread implementation.
Improving the neurodevelopmental trajectory of children born preterm remains a challenge for obstetricians and paediatricians. Advances in obstetric care and neonatal resuscitation have made it possible for increasingly more neonates born preterm to survive, but preterm birth is still the leading cause of infant mortality across the world, particularly in emerging countries. Exacerbating the matter, significant neurological morbidities (e.g. cognitive and behavioural disabilities, sensorimotor deficiencies, and cerebral palsy [CP] ) require prolonged hospitalization and care with very high costs and diminish the quality of life of the affected children and their families. CP was defined by Rosenbaum et al. as 'a group of permanent disorders of the development of movement and posture, causing activity limitation, that are attributed to non-progressive disturbances that occurred in the developing fetal or infant brain. The motor disorders of CP are often accompanied by disturbances of sensation, perception, cognition, communication, and behaviour, by epilepsy, and by secondary musculoskeletal problems'. 1 Since 1980, the rate of CP in children born preterm has declined in Europe. 2 In France the rate of CP decreased from 9 per cent in children born very preterm in 1997 to 5.4 per cent in 2011. 3 The purpose of this review is to compile and analyse the existing scientific data (pharmacological effects, experimental data, observational epidemiological studies, and randomized trials) concerning the antenatal use of magnesium sulphate as a protective measure against CP in children born preterm.
MATERIAL AND METHODS
A bibliographic search was made using MEDLINE databases and the Cochrane Library. The following key words were selected and combined in as many steps as necessary: 'preterm birth', 'spontaneous delivery', 'premature rupture of membranes', 'preeclampsia', 'eclampsia', 'induced delivery', 'risk factor', 'outcome', 'mortality', 'morbidity', 'cerebral palsy', 'neurodevelopment', 'population-based', and 'magnesium'. Only English and French language publications were selected.
DEVELOPMENTAL DISRUPTION IN THE PRETERM NEONATAL BRAIN
The encephalopathy of preterm birth results from a state of cerebral vulnerability and exposure to specific risk factors. Several features of the preterm neonatal brain make it particularly vulnerable, including: [4] [5] [6] [7] (1) abrupt interruption of the supply of hormones, growth factors, and nutrients provided by the maternal-placental unit to the fetal brain; (2) persistent activity of the subependymal zone, characterized by glial cell production and extensive angiogenesis with fragile growing endothelial cells and fragile endothelial cells; (3) vulnerability of white matter in the active phase of glial and axonal development, characterized by massive production of neurotransmitter receptors and microglial cells, migration of preoligodendrocytes (or oligodendrocytes in development) and GABAergic neurons, and the presence of transient neurons in the subplate; and (4) functional immaturity of cortical and basal ganglia neurons, as well as variable sensitivity (excitotoxic or trophic) to neurotransmitters in different neuronal layers, with upper layers reaching less mature forms than deeper layers because of their diminished sensitivity.
In most cases, no single causal factor can account for brain lesions and the resulting disabilities. Instead, a set of predisposing factors altering brain maturation -chronic, subacute, or acute; prenatal, perinatal, or postnatal; hypoxicischemia or inflammatory -lead to the onset of CP or other neurodevelopmental sequelae.
MAGNESIUM: BIOLOGICAL PERSPECTIVES
Magnesium is involved in several essential metabolic functions within the cell: glycolysis and oxidative phosphorylation, enzymatic systems, cell membrane integrity, protein synthesis, aggregation of DNA and ribonucleic acid neuromuscular excitability, and nerve conduction. 8 In the central nervous system, magnesium forms an essential component of nicotinic acetylcholine receptors, G protein-coupled acetylcholine receptors, N-methyl-D-aspartate glutamate receptors, b-adrenergic receptors, L-type calcium channels, and Na + -K + adenosine triphosphate-dependent pumps. 8 Via these roles, magnesium occupies a key place in cell death and developmental processes. A systematic review published in 2017 found that magnesium levels at birth were similar to that of mothers during pregnancy (0.76mmol/L; 95% confidence interval [CI]: 0.52, 0.99), but the level usually increases during the first week of life (0.91mmol/L; 95% CI: 0.55, 1.26). Transplacental passage of magnesium is well established. With maternal magnesium supplementation during pregnancy, the average concentration becomes 1.25mmol/L (95% CI: 0.47, 2.03) at birth and 1.48mmol/L (95% CI: 0.64, 2.32) on the first day after birth. Serum magnesium concentrations up to 2.0mmol/L appear to be well tolerated in neonates; administration requires adequate surveillance but minimal intervention. 9 
MECHANISMS INVOLVED IN THE NEUROPROTECTIVE EFFECTS OF MAGNESIUM SULPHATE: PRECLINICAL STUDIES
In vitro and in vivo animal models of inflammatory/hypoxicischemic/excitotoxic neonatal brain lesions have revealed that magnesium plays a role in the mechanisms involved in the death or dysfunction of endothelial cells, neurons, astrocytes, oligodendrocyte precursors, and synapses.
In rats, administration of magnesium sulphate before focal cerebral ischemia significantly reduces infarct size. 10 Administration also reduces the size of lesions induced by intraspinal injection of N-methyl-D-aspartate or intracerebral injection of ibotenate, 11, 12 and reduces neuro-apoptosis after hypoxia-ischemia. 13 In mice, magnesium sulphate prevents long-term sensorimotor alteration induced by intracortical ibotenate injection or hypoxia-ischemia. 14, 15 Moreover, magnesium sulphate has been shown to decrease the production of free radicals and proinflammatory cytokines during reperfusion after ischemia or inflammation. 9 Magnesium's anti-inflammatory properties are also observed in vitro in cord blood mononuclear cells of the human neonate. 16 The rate of brain-derived neurotrophic factor production is correspondingly elevated in the cord blood of infants born preterm whose mothers received magnesium sulphate, which is consistent with an anti-inflammatory effect. 17 In a murine model of perinatal neuroinflammation, long-term sex-specific benefits were observed in magnesium sulphate/betamethasone-treated cases relative to a placebo group. The sex-specific effect favoured males; a minimal injury causing a greater alteration to gene control among females, or a heightened susceptibility to magnesium or betamethasone among males, may account for the sex-specific discrepancy. 18 Magnesium sulphate can also prevent excitotoxic glutaminergic cell death induced by excess intracellular calcium. The latter is related to a decrease in presynaptic glutamate release: magnesium attaches to an intrachannel site on the N-methyl-Daspartate glutamate receptor, inducing a potentiation of presynaptic adenosine receptors, or a noncompetitive blockade of voltage-gated calcium channels.
In cortical slices of mice pups, a dose-dependent deleterious effect of magnesium sulphate on cerebral angiogenesis was noted. An elevated dosage of magnesium sulphate (not achieved using human protocols) induced brain hypoperfusion, and affected cortical angiogenesis and endothelial cell survival. 19 Thus, although the full effects of magnesium sulphate are not yet well understood, magnesium clearly exerts antiinflammatory and anti-excitotoxic effects that could underlie its neuroprotective properties. However, the sex-specific actions and deleterious impact when used at high dosage need to be confirmed with other experimental studies.
NEUROPROTECTIVE EFFECTS OF MAGNESIUM SULPHATE IN CLINICAL OBSERVATIONAL STUDIES
A meta-analysis on a series of observational studies showed that prenatal magnesium sulphate administration was associated with a significant drop in infant mortality in five cohort studies involving 2826 children (relative risk 0.73; 95% CI: 0.61-0.89), as well as a significant drop in CP, among five case-control studies involving 974 children (odds ratio [OR] 0.64; 95% CI: 0.47-0.89). 20 This meta-analysis, however, was inherently limited by the retrospective design of the analysed studies. The report was further marred by a lack of data on the doses of magnesium sulphate used, the absence of randomization, and the lack of stratification by study type (cohort and casecontrol).
What this paper adds
• Neuroprotective effect of magnesium sulphate to reduce cerebral palsy in infants born preterm when administered to females at risk of imminent preterm birth.
• Neuroprotection regardless of gestational age, cause of preterm birth, and total dose.
• Antenatal magnesium sulphate treatment has good cost-effectiveness.
A more recent prospective observational study noted that antenatal exposure to magnesium sulphate is associated with a reduction in late-MRI-diagnosed cerebellar haemorrhages in infants born preterm before 33 weeks' gestation (OR 0.18, 95% CI: 0.049-0.65, p=0.09). 21 Finally, the prospective national population-based cohort study EPIPAGE 2 included all infants born preterm in 25 regions of France born in 2011 at 22 to 34 weeks' gestation. It found that less than 10 per cent of these children (345) were exposed to antenatal administration of magnesium sulphate. In contrast, rates were as high as 90 per cent in the Haute-Normandie region. A recent EPIPAGE 2 benchmarking study in several regions in France observed that the rate of CP in Haute-Normandie (2/87; 2.1%; range: 0.2%-7.7%]) was half that in France overall (4.6%; 95% CI: 3.9-5.5). 3 
NEUROPROTECTIVE EFFECTS OF MAGNESIUM SULPHATE IN RANDOMIZED TRIALS
Four randomized controlled trials using magnesium sulphate for cerebral neuroprotection have been performed (MAGnet, ACTOMgSO 4 , PREMAG, BEAM). [22] [23] [24] [25] [26] In each trial, magnesium sulphate was administered to females with imminent preterm delivery at a loading dose of 4g to 6g. In three out of four trials, additional magnesium sulphate was administered in maintenance doses of 1g/h to 2g/h. A fifth trial was conducted to prevent eclampsia in females with pre-eclampsia (the Magpie Trial Collaborative Group). 27 Females were randomly assigned to receive a placebo or a 4g loading dose of magnesium sulphate , followed by a maintenance dose of 1g/h or 5g every 4 hours over the course of a day. The investigation included 1544 females and 1593 children born before 34 weeks' gestation; females giving birth beyond this term were not included in the analysis. The results of the primary combined endpoints of these trials are shown in Table I .
An excess of paediatric mortality in the magnesium sulphate group relative to the placebo group prompted the Food and Drug Administration to halt the MAGnet trial before it was completed. This premature termination was disputed: though the mortality rate in the magnesium sulphate group was near the expected death rate (10.3%) given the gestational age at delivery, the mortality rate was abnormally low in the placebo group (1.3%). 28 The other randomized trials, however, featured similar mortality rates in both groups.
Impact on acquired neonatal brain injuries: results of randomized controlled trials ACTOMgSO 4 , a multicentre Australasian trial, observed no group differences in intracranial haemorrhage rates (all grades; 27.7% for 620 children in the magnesium sulphate group vs 25.3% for the 615 children in the placebo group), severe intracranial haemorrhage rates (stage III and IV) (8.2% vs 8.5%), or periventricular leukomalacia rates (3.7% vs 3.6%). 23 In PREMAG, a French trial, a nonsignificant decrease in white matter disease diagnosed by transfontanellar ultrasound was observed in a group of 352 children whose mothers received magnesium sulphate (15.8%) compared to 336 children whose mothers received a placebo (18.2%; adjusted OR 0.79; 95% CI: 0.51-1.22). 24 In the American BEAM multicentre trial, transfontanellar ultrasound did not reveal a significant difference in the frequency of cerebral abnormalities in the initial randomized trial of 2296 children (severe intracranial haemorrhage [III or IV] magnesium sulphate: 2.1% vs placebo 3.2%, relative risk 0.64; 95% CI: 0.38-1.06; periventricular leukomalacia magnesium sulphate 1.9% vs placebo 2.3%, relative risk 0.83; 95% CI: 0.47-1.45). 26 A secondary analysis of the 1979 surviving children followed at 2 years (94% of 2110 children were discharged alive) noted a significant decrease in white matter disease among those from the magnesium sulphate group. 29 Neuroprotective effects of magnesium sulphate on neurological outcomes at 2 years: results of metaanalyses
The four aforementioned randomized controlled trials set up to evaluate the neuroprotective effect of magnesium sulphate have been pooled, along with the Magpie trial set up to study the treatment of severe pre-eclampsia or eclampsia, in four meta-analyses that have yielded definitive conclusions. [30] [31] [32] [33] In all the meta-analyses, antenatal magnesium sulphate administered to females at risk of preterm delivery was associated with a significantly reduced risk of CP for children exposed in utero (the relative risk ranged from 0.61 to 0.70 according to the meta-analysis), but not with reductions in neonatal and paediatric death. The number of females needed to treat to prevent one case of CP in infants born before 34 weeks' gestation ranged from 56 to 74; for those born before 29 weeks' gestation, the number needed to treat was 29 (Table I) . Minor maternal side effects (e.g. flushing, nausea or vomiting, sweating, discomfort at the injection site) were higher in the magnesium groups, but there was no significant increase in serious maternal complications. No side effects were observed in children born preterm exposed to magnesium sulphate.
Meta-analyses are, however, usually based on aggregated data extracted from publications or obtained from trial investigators. Individual personal data meta-analyses, involving the central collection and analysis of individual data for the participants in each trial, are usually conducted as international collaborative projects. They can surpass the limitations of standard meta-analyses, because they use data that is superior both in quantity and quality, allow for greater scope in their analyses, and provide more detailed, robust results. An individual personal data meta-analysis was undertaken by the AMICABLE group to explore the interaction between treatment and participant characteristics. 34 In that study, the five randomized controlled trials aforementioned were included (i.e. 5493 females and 6131 infants). The overall relative risk of CP among survivors after antenatal magnesium sulphate was 0.68 (95% CI: 0.54-0.87), and the number needed to treat was 46. 27 Doyle et al. 30 Conde-Agudelo et al. 31 Costantine et al. 32 Zeng et al. 33 Crowther et al. 34 Paediatric mortality Interestingly, analysis of the four trials with fetal neuroprotective intent revealed that magnesium sulphate also reduced the combined risk of fetal/infant death and CP (relative risk 0.86, 95% CI: 0.75-0.99). In agreement with the results of the randomized controlled trials and metaanalyses, magnesium sulphate treatment had no effect on neonatal and paediatric mortality, or neonatal morbidity (respiratory distress syndrome, chronic lung disease, intraventricular haemorrhage, cystic periventricular leukomalacia, necrotizing enterocolitis, patent ductus arteriosus, or retinopathy of preterm birth). Similarly, magnesium sulphate treatment was not associated with serious maternal side effects. The benefit remained similar regardless of gestational age, cause of preterm birth, total dose received, or administration of a maintenance dose after the loading dose. These data concerning the persistence of the benefits, regardless of the dose of magnesium sulphate, are particularly intriguing: they favour the use of low doses (e.g. 4g loading dose plus 1g/h maintenance dose over 12 hours with a maximum total dose received of 16g) over high doses (e.g. 6g loading dose + 2g/h maintenance dose over 24h with a maximum total dose received of 54g). Indeed, high doses of magnesium sulphate were implicated in the excess of mortality observed in the infants exposed to magnesium in the MAGnet trial, as well as in the occurrence of vasculopathy. Combined with the results of the preclinical study of Lecuyer et al., 19 the individual personal data meta-analysis results support the use of magnesium sulphate in low doses.
Outcomes at school age for ACTOMgSO 4 and PREMAG cohorts A follow-up was performed of cohorts of children at school age included in two out of four randomized trials (ACTOMgSO 4 and PREMAG). 35, 36 In a study performed by Doyle et al., 36 669 out of 867 eligible children (77%) were evaluated for motor, neuropsychological, attentional, executive, and behavioural functions. Magnesium sulphate administered to females at imminent childbirth before 30 weeks' gestation was not associated with better neurological, cognitive, or behavioural outcomes by school age (6-11y) (CP: magnesium sulphate group 8% vs placebo group 7%; relative risk, 1.26, 95% CI: 0.84-1.91). The children did not show significant improvements in motor development abnormalities (magnesium sulphate group 27% vs placebo group 27%; relative risk, 1.16; 95% CI: 0.88-1.52). However, a trend toward a decrease in mortality through school age was observed (relative risk, 0.80; 95% CI: 0.62-1.03; p=0.08). In the PREMAG trial, 431 children were assessed using a postal questionnaire at an average age of 11 years (7-14y were noted in the group of children whose mothers received magnesium. However, the power of the studies is limited because of the number of patients lost to follow-up (27% in the PREMAG trial and 23% in the ACTOMgSO 4 trial), as well as because of biases related to the possible effects of many unrecognized postnatal confounding factors.
PERSPECTIVES AND CONCLUSIONS
The development of children born preterm is a long and complex process. The best strategy for protecting the neonatal brain has yet to be established. It is unlikely that we will find a single molecule capable of protecting the entire developmental trajectory of children born preterm; interventions must instead be based on a set of measures that include the removal of several risk factors (antenatal, perinatal, and postnatal), the use of neuroprotective molecules, and educational strategies.
The antenatal administration of intravenous magnesium sulphate has demonstrated its utility in reducing the prevalence of CP in infants born preterm; moreover, the drug is cost-effective. 37 Several obstetrical societies, as well the World Health Organization, have recommended the antenatal administration of magnesium sulphate to females at risk of imminent preterm birth from 23 to 32 weeks' gestation. In 2017, the French College of Obstetricians published recommendations on the prevention of spontaneous preterm birth. 38 They recommended that magnesium sulphate be administered to females in whom delivery before 32 weeks' gestation is imminent, expected, or scheduled, with a loading dose of 4g intravenously followed by a maintenance dose of 1g/h for 12 hours, regardless of the cause of preterm birth or whether the pregnancy is single or multiple. Magnesium sulphate is therefore qualified to be used as a definitive intervention to prevent or to treat preterm birth-related disabilities, and as an agent to optimize brain development at a period of high cerebral vulnerability caused by the abrupt alteration of the neonate's environment.
RESUMEN PROTECCI ON DEL DESARROLLO CEREBRAL MEDIANTE SULFATO DE MAGNESIO PRENATAL PARA BEB ES NACIDOS PREMATUROS
La par alisis cerebral (PC) sigue siendo el trastorno neurol ogico m as significativo asociado con el nacimiento prematuro. Impacta en la calidad de vida y genera enormes cargas de costos para la sociedad. La administraci on prenatal de sulfato de magnesio a las mujeres antes de las 32 semanas de gestaci on ha demostrado ser una intervenci on efectiva para reducir la tasa de PC. En los modelos de hipoxia, hipoxia-isquemia, inflamaci on y excitotoxicidad en diversas especies animales, la administraci on de sulfato de magnesio disminuy o los tamaños de las lesiones resultantes y los niveles de citocinas inflamatorias, evit o la muerte celular y mejor o los comportamientos cognitivos y motores a largo plazo. En humanos, los metan alisis de cinco ensayos controlados aleatorios que usaron sulfato de magnesio como neuroprotector mostraron prevenci on de PC a los 2 años. El beneficio se mantuvo constante independientemente de la edad gestacional, la causa del parto prematuro y la dosis total recibida. El tratamiento con sulfato de magnesio prenatal ahora es recomendado por la Organizaci on Mundial de la Salud y por muchas sociedades obst etricas. Su costo-efectividad justifica a un m as su implementaci on generalizada.
RESUMO PROTEC ßÃO DO DESENVOLVIMENTO CEREBRAL COM SULFATO DE MAGN ESIO ANTENATAL PARA LACTENTES NASCIDOS PREMATUROS
A paralisia cerebral (PC) permanece sendo a desordem neurol ogica mais significativa associada ao nascimento prematuro. Ela afeta a qualidade de vida e tem alto custo para a sociedade. A administrac ßão antenatal de sulfato de magn esio para mulheres antes de 32 semanas de gestac ßão se mostrou uma intervenc ßão efetiva para reduzir a taxa de PC. Em modelos de hip oxia, hip oxiaisquemia, inflamac ßão e excitotoxidade em v arias esp ecies animais, o sulfato de magn esio diminuiu as lesões resultantes e os n ıveis de citocinas inflamat orias, diminuiu a morte celular, e melhorou os comportamentos cognitivos e motores no longo prazo. Em humanos, metan alises de cinco estudos randomizados controlados usando sulfato de magn esio como neuroprotetor mostrou prevenc ßão da PC aos 2 anos de idade. O benef ıcio permaneceu consistente independente da idade gestacional, causa do nascimento prematuro, e dose total recebida. O tratamento antenatal com sulfato de magn esio e agora recomendado pela Organizac ßão Mundial de Sa ude e por muitas sociedades obst etricas. Seu custo-efetividade justifica ainda mais sua implementac ßão ampliada.
